# MCUJF catalysts: MEDICURE INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mcujf/catalysts

> MEDICURE INC (MCUJF) has 4 upcoming catalysts. The next is the pyridoxal phosphate primary completion, September 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | MEDICURE INC |
| Ticker | MCUJF (OTC) |
| SEC CIK | 1133519 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mcujf |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 14, 2017 | [ZYPITAMAG® (pitavastatin) FDA approval](https://sec-api.dev/pdufa/pitavastatin) | MCUJF |  | completed, approved | "NDA208379 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20170714, review_priority STANDARD; sponsor_name MEDICURE; product ZYPITAMAG (PITAVASTATIN MAGNESIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208379%22)) |
| September 2027 | [Pyridoxal phosphate primary completion](https://sec-api.dev/pdufa/pyridoxal) | MCUJF | Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency | scheduled | "NCT04706013 (Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Medicure." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04706013)) |
| Sep to Dec 2027 | [Pyridoxal phosphate topline data readout](https://sec-api.dev/pdufa/pyridoxal) | MCUJF | Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency | scheduled | "NCT04706013 (Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Medicure." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04706013)) |
| Jul to Oct 2029 | [Pyridoxal 5'-phosphate topline data readout](https://sec-api.dev/pdufa/pyridoxal-5) | MCUJF | Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency | scheduled | "NCT07928388 (Continuation Study With Oral MC-1 for Treatment of Patients With PNPO-Deficiency): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-15 (ESTIMATED); Lead Sponsor Medicure." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07928388)) |
| July 2029 | [Pyridoxal 5'-phosphate primary completion](https://sec-api.dev/pdufa/pyridoxal-5) | MCUJF | Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency | scheduled | "NCT07928388 (Continuation Study With Oral MC-1 for Treatment of Patients With PNPO-Deficiency): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-15 (ESTIMATED); Lead Sponsor Medicure." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07928388)) |

## Drugs

- [ZYPITAMAG® (pitavastatin)](https://sec-api.dev/pdufa/pitavastatin): disseminated superficial actinic porokeratosis planned for second half of 2026, disseminated superficial actinic porokeratosis planned for the second half of 2026
- [Pyridoxal phosphate](https://sec-api.dev/pdufa/pyridoxal): Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
- [Pyridoxal 5'-phosphate](https://sec-api.dev/pdufa/pyridoxal-5): Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mcujf/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MCUJF catalysts: MEDICURE INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mcujf/catalysts

```bibtex
@misc{secapidev_companies_mcujf_catalysts_20261116,
  title        = {MCUJF catalysts: MEDICURE INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mcujf/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mcujf_catalysts_20261116","title":"MCUJF catalysts: MEDICURE INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mcujf/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
